Professor Meg Jardine is the Director of the CTC and the CTC’s Kidney Health Research Director. Her research focusses on reducing the progression and complications of non-communicable diseases - particularly kidney disease, diabetes and cardiovascular disease - through randomised trials and epidemiological analyses.

Meg is an accomplished clinical trialist who has used and created innovative design features in trials, including cluster randomized designs, simplified consent procedures, adaptive endpoint determination, randomised rescue protocols, and algorithm-based monitoring systems for trials embedded in routine clinical care. She has promoted learning health system principles through the integration of clinical care and research endeavours, and she has played leading roles in global and national indication and comparative effectiveness trials, working in partnership with the clinical community, consumers, sponsors and health services.

Meg is also a member of the International Society of Nephrology Executive Committee (2023 - 2025), an Executive Committee member of the international nephrology guidelines body, KDIGO, and has contributed to Australian CARI guideline development. She contributes to policy setting and implementation through roles such as Board Member of the Kidney Health Initiative, a public-private collaboration of the American Society of Nephrology, and the US FDA. She advocates for kidney disease trials in roles with the Australasian Kidney Trials Network, the International Society of Nephrology Advancing Clinical Trials (ISN-ACTS) core committee, and the ANZSN Research Advisory Committee. Meg joined the CTC from The George Institute where she was Program Head of Innovation & Kidney Research. She is a practising nephrologist at Concord Repatriation General Hospital.

Meg was honoured with the T.J.Neale award for Outstanding Contribution to Nephrological Science in 2020.